Physician profile
Mohammad Abdallah
NPI 1598251282
$2,898.88
in general payments reported to CMS, 2019-2025
17 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $255 · 2023: $796 · 2024: $1,637 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $738.17 | 2023-2025 | Mavyret, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $368.41 | 2022-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $275.79 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $237.89 | 2023 | Zeposia |
| Janssen Biotech, INC. | $226.24 | 2024 | Stelara, Tremfya |
| Erbe USA INC | $202.70 | 2023 | Erbe Vio3 |
| Madrigal Pharmaceuticals | $141.42 | 2024 | Rezdiffra |
| Lilly USA, LLC | $122.01 | 2024 | Omvoh |
| Ardelyx, INC. | $119.02 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $105.21 | 2024 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $101.49 | 2022 | |
| Capsovision, INC. | $82.89 | 2024 | Capsocam Plus |
| Genzyme Corporation | $66.64 | 2024 | |
| Novo Nordisk INC | $51.09 | 2022-2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $22.49 | 2023 | Rebyota |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.53 | 2025 | |
| Aimmune Therapeutics, INC. | $17.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Abdallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.